Year All2023202220212020 June 26, 2023 Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19 June 22, 2023 Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People June 1, 2023 Invivyd to Participate at the Jefferies Healthcare Conference May 11, 2023 Invivyd Reports First Quarter 2023 Financial Results and Business Highlights May 4, 2023 Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights April 25, 2023 Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference April 25, 2023 Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update April 12, 2023 Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer March 30, 2023 Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19 March 23, 2023 Invivyd Reports Full Year 2022 Financial Results and Business Highlights
